Brain Boost for Veterans: Congress Backs Neuro-Tech for TBI, PTSD

HOUSTON, TX – February 23, 2026 – By Carol Thomas

A series of recent bipartisan actions on Capitol Hill are signaling a major federal shift toward embracing cutting-edge brain technology, with a particular focus on America's veterans. New appropriations language and proposed legislation aim to accelerate research into deep brain neurostimulation, a field that promises new hope for intractable conditions like Traumatic Brain Injury (TBI), PTSD, and Alzheimer's disease. This legislative momentum, actively championed by companies like Houston-based Nexalin Technology, Inc., could unlock a new frontier of treatment for millions.

Nexalin, a developer of non-invasive brain stimulation technology, commended the congressional push, which aligns directly with its own clinical work and strategic goals. The company's advocacy division, Nexalin America, participated in efforts to shape the legislative language, highlighting a growing trend where MedTech firms are not just inventing therapies but also helping to create the policy frameworks that bring them to patients.

A New Wave of Federal Support

The increased federal focus is codified in key legislative reports accompanying the 2026 appropriations bills, which have been signed into law. S. Rept. 119-43, accompanying the Military Construction and Veterans Affairs funding bill, specifically directs the Department of Veterans Affairs (VA) to expand neuromodulation research, highlighting its potential for aiding stroke recovery among veterans.

Similarly, H. Rept. 119-271, tied to the funding for the Department of Health and Human Services, expands National Institutes of Health (NIH) support for non-human primate research using deep brain stimulation for devastating neurodegenerative conditions like Alzheimer’s and Parkinson’s disease.

Collectively, these directives inject significant institutional and financial weight behind a field that was once the domain of science fiction. They represent a formal recognition that new tools are needed to combat neurological and psychiatric disorders.

Nexalin also pointed to H.R. 7091, the “Expanding Veterans’ Access to Emerging Treatments Act,” as a critical piece of this movement. The proposed bill aims to further expand clinical trials and establish a compassionate use pathway for emerging therapies like deep brain neurostimulation within the vast VA healthcare system. While the specific bill number for the current congressional session could not be independently verified in public legislative databases, the principles it represents are a core part of the advocacy efforts underway.

“These legislative developments reflect growing national recognition of neurostimulation technologies as a potential breakthrough category of care,” said Mark White, Chief Executive Officer of Nexalin, in a public statement. “We deeply appreciate Congress’s strong voice in helping to bolster potentially transformational therapies for America’s heroes.”

The Veteran Crisis and the Promise of Neuro-Tech

The focus on veterans is no accident. TBI has been called a signature wound of the post-9/11 conflicts, with the VA reporting over 450,000 diagnoses since 2000. PTSD affects a significant percentage of veterans across different eras, with many finding that conventional treatments like medication and psychotherapy offer only partial relief or fail entirely. For this treatment-resistant population, the need for innovation is acute.

This is where neurostimulation enters the picture. The technology, in its various forms, seeks to modulate the disordered brain circuits that underlie these conditions. The federal push aims to accelerate the validation and potential deployment of these therapies within the VA, which is actively seeking new solutions for its patients.

A tangible example of this promise is already underway in California. Nexalin is currently sponsoring a clinical trial at UC San Diego in partnership with the local VA community. The study is evaluating the company's proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology for veterans suffering from chronic TBI symptoms. This double-blind, sham-controlled trial—the gold standard in clinical research—aims to provide the rigorous data needed to prove the therapy's effectiveness.

From Surgical Wires to Invisible Waves

When many think of deep brain stimulation (DBS), they picture the established, invasive version—a surgical procedure involving the implantation of electrodes deep within the brain. While highly effective and FDA-approved for conditions like Parkinson's disease and essential tremor, the surgical risks have limited its application for psychiatric conditions or less severe disorders.

The new frontier, where Nexalin and a host of competitors operate, is in non-invasive neuromodulation. These technologies aim to influence deep brain structures from outside the skull, using methods like magnetic fields (TMS) or electrical currents. Nexalin’s DIFS™ technology is designed to deliver a unique frequency-based waveform that, the company believes, can penetrate deeper into the mid-brain structures associated with mental health disorders without the side effects or risks of surgery.

This non-invasive approach is key to potentially wider adoption. If proven effective, it could offer a scalable, lower-risk treatment option that could be administered in a clinical setting without a hospital stay, dramatically increasing accessibility for veterans and the general population.

The Business of Brainwaves: Policy, Lobbying, and Market Position

The recent legislative successes are not just a win for patients; they are a case study in modern MedTech strategy. Public lobbying disclosure records confirm that Nexalin has been actively engaged in Washington, advocating for appropriations language that supports neurostimulation research. This proactive policy engagement is crucial for emerging technologies that require not only scientific validation but also a clear regulatory and reimbursement pathway to market.

By helping to shape the federal conversation, the company is effectively helping to build the market for its own products. This alignment of corporate strategy with public health needs demonstrates a sophisticated understanding of the modern healthcare landscape. The federal support serves as a powerful de-risking event, signaling to investors and the broader medical community that neurostimulation is a national priority.

The potential market is vast. TBI, PTSD, stroke, Alzheimer's, and Parkinson's represent multi-billion-dollar addressable markets characterized by significant unmet needs. As these federal research initiatives bear fruit, companies well-positioned with validated, non-invasive technologies could see substantial growth. The competitive landscape is fierce, with established giants like Medtronic and Boston Scientific in the invasive space and a dynamic field of non-invasive players. However, the expanding federal support and focus on veteran health may provide a powerful tailwind for companies like Nexalin, whose technology and clinical focus are squarely aligned with these emerging national priorities.